Champions Historical Cash Flow
| CSBR Stock | USD 9.11 0.39 4.11% |
Analysis of Champions Oncology cash flow over time is an excellent tool to project Champions Oncology future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 276.4 K or Depreciation of 2.3 M as it is a great indicator of Champions Oncology ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Champions Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Champions Oncology is a good buy for the upcoming year.
Champions |
About Champions Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Champions balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Champions's non-liquid assets can be easily converted into cash.
Champions Oncology Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Champions Oncology's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Champions Oncology current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.At this time, Champions Oncology's Change Receivables is relatively stable compared to the past year.
Champions Oncology cash flow statement Correlations
Click cells to compare fundamentals
Champions Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Champions Oncology cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | 1.4M | 207K | (74K) | (634K) | (729.1K) | (692.6K) | |
| Change In Cash | (3.7M) | 4.3M | 1.1M | (7.5M) | (6.8M) | (6.4M) | |
| Free Cash Flow | (5.0M) | 4.1M | 1.1M | (7.0M) | (6.3M) | (6.0M) | |
| Change In Working Capital | (4.2M) | 2.3M | 4.2M | (3.8M) | (4.4M) | (4.2M) | |
| Begin Period Cash Flow | 8.3M | 4.7M | 9.0M | 10.1M | 11.6M | 12.2M | |
| Other Cashflows From Financing Activities | 1.4M | 207K | 85K | 253K | 291.0K | 276.4K | |
| Depreciation | 1.2M | 1.6M | 2.2M | 1.9M | 2.1M | 2.3M | |
| Other Non Cash Items | 323K | 1.1M | 952K | 2.0M | 2.3M | 2.4M | |
| Capital Expenditures | 3.3M | 2.4M | 2.9M | 836K | 961.4K | 610.0K | |
| Total Cash From Operating Activities | (1.7M) | 6.5M | 4.0M | (6.1M) | (5.5M) | (5.2M) | |
| Change To Account Receivables | (2.3M) | (2.8M) | 1.3M | (2.0M) | (1.8M) | (1.7M) | |
| Net Income | 334K | 548K | (5.3M) | (7.3M) | (6.5M) | (6.2M) | |
| Total Cash From Financing Activities | 1.2M | 207K | 11K | (527K) | (606.1K) | (575.7K) | |
| End Period Cash Flow | 4.7M | 9.0M | 10.1M | 2.6M | 3.0M | 3.7M | |
| Change To Liabilities | 3.5M | (805K) | 6.0M | 4.0M | 4.6M | 4.9M | |
| Total Cashflows From Investing Activities | (2.2M) | (3.2M) | (2.4M) | (2.9M) | (2.6M) | (2.5M) | |
| Stock Based Compensation | 598K | 912K | 864K | 1.1M | 1.0M | 1.3M | |
| Change Receivables | (670K) | (2.3M) | (2.8M) | 1.3M | 1.2M | 1.2M | |
| Cash And Cash Equivalents Changes | 5.1M | (3.7M) | 4.3M | 1.1M | 1.3M | 877.4K | |
| Cash Flows Other Operating | 91K | (491K) | (32K) | (139K) | (125.1K) | (118.8K) | |
| Change To Operating Activities | 1.0M | (1.1M) | 2.3M | (1.2M) | (1.4M) | (1.4M) | |
| Change To Netincome | 1.2M | 970K | 1.2M | 1.9M | 1.7M | 1.6M | |
| Investments | (3.2M) | (2.4M) | (2.9M) | (836K) | (752.4K) | (790.0K) |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Champions Stock
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.